

# Payam Tabarsi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/854601/publications.pdf>

Version: 2024-02-01

207  
papers

6,056  
citations

126708

33  
h-index

85405

71  
g-index

217  
all docs

217  
docs citations

217  
times ranked

10190  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary manifestations in a cohort of patients with inborn errors of immunity: an 8-year follow-up study. <i>Allergologia Et Immunopathologia</i> , 2022, 50, 80-84.	1.0	3
2	Extracellular vesicles from serum samples of mycobacteria patients induced cell death of THP-1 monocyte and PBMC. <i>BMC Pulmonary Medicine</i> , 2022, 22, 57.	0.8	1
3	Transmission electron microscopy study of suspected primary ciliary dyskinesia patients. <i>Scientific Reports</i> , 2022, 12, 2375.	1.6	3
4	Mixed etiology COVID-19 associated acute rhinosinusitis caused by two <i>Aspergillus</i> species. <i>Annals of Medicine and Surgery</i> , 2022, 75, 103365.	0.5	6
5	Coinfection by <i>Aspergillus</i> and <i>Mucoraceae</i> Species in Two Cases of Acute Rhinosinusitis as a Complication of COVID-19. <i>Case Reports in Medicine</i> , 2022, 2022, 1-6.	0.3	4
6	Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2022, 21, 8.	1.7	7
7	Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. <i>BMJ Open</i> , 2022, 12, e056872.	0.8	12
8	Safety and immunogenicity of SpikoGen <sup>®</sup> , an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1263-1271.	2.8	37
9	Investigation of two general venous thromboembolism risk-stratification models in predicting venous thromboembolic events in TB patients. <i>International Journal of Mycobacteriology</i> , 2022, 11, 83.	0.3	0
10	Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature. <i>Immunological Investigations</i> , 2021, 50, 884-890.	1.0	18
11	Management of ST-segment elevation myocardial infarction during the coronavirus disease 2019 (COVID-19) by percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E346-E351.	0.784314	17
12	Myocarditis detected after COVID-19 recovery. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 131-132.	0.5	26
13	Clinical and demographic characteristics of patients with COVID-19 infection: Statistics from a single hospital in Iran. <i>Human Antibodies</i> , 2021, 29, 49-54.	0.6	4
14	Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. <i>International Immunopharmacology</i> , 2021, 90, 107205.	1.7	64
15	SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 473-481.	4.6	132
16	COVID-19: Molecular and Cellular Response. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 563085.	1.8	31
17	Combination therapy of IFN- $\beta$ 1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. <i>International Immunopharmacology</i> , 2021, 92, 107329.	1.7	15
18	No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. <i>European Journal of Pharmacology</i> , 2021, 897, 173947.	1.7	66

#	ARTICLE	IF	CITATIONS
19	Increased Serum Levels of Soluble TNF- $\alpha$ Receptor Is Associated With ICU Mortality in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 592727.	2.2	53
20	Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2021, 2021, 1-6.	0.7	10
21	Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra. <i>International Immunopharmacology</i> , 2021, 93, 107407.	1.7	16
22	Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. <i>Human Antibodies</i> , 2021, 29, 109-113.	0.6	7
23	Single-pill sofosbuvir and daclatasvir for treating hepatitis C in patients co-infected with human immunodeficiency virus. <i>International Journal of Clinical Practice</i> , 2021, 75, e14304.	0.8	2
24	Decreased neutrophil-mediated bacterial killing in COVID-19 patients. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13083.	1.3	7
25	Case Report: COVID-19-associated Rhinosinusitis Mucormycosis Caused by <i>Rhizopus arrhizus</i> : A Rare but Potentially Fatal Infection Occurring After Treatment with Corticosteroids. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 449-453.	0.6	26
26	Leukocytoclastic vasculitis in patients with IL12B or IL12RB1 deficiency: case report and review of the literature. <i>Pediatric Rheumatology</i> , 2021, 19, 121.	0.9	8
27	Coronavirus disease 2019 outcomes in heart transplant recipients: a single-center case series. <i>Journal of Medical Case Reports</i> , 2021, 15, 453.	0.4	3
28	IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients. <i>International Immunopharmacology</i> , 2021, 99, 107998.	1.7	4
29	Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial. <i>International Immunopharmacology</i> , 2021, 99, 108043.	1.7	2
30	Potential diagnostic value of pleural fluid cytokines levels for tuberculous pleural effusion. <i>Scientific Reports</i> , 2021, 11, 660.	1.6	12
31	Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). <i>Pulmonology</i> , 2021, 27, 486-492.	1.0	33
32	Relapse of Lymphangioliomyomatosis Five Years after Bilateral-Lung Transplantation. <i>Archives of Iranian Medicine</i> , 2021, 24, 701-703.	0.2	0
33	Diagnosis of COVID-19 by Serology in Admitted Patients with Negative RT-PCR Assay. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2021, 20, 394-401.	0.3	0
34	Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form.. <i>Iranian Journal of Pharmaceutical Research</i> , 2021, 20, 1-8.	0.3	10
35	Tocilizumab as a promising agent against COVID-19: Issues and challenges. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 80.	0.4	0
36	Efficacy of Early Prone Positioning Combined with Noninvasive Ventilation in COVID-19.. <i>Tanaffos</i> , 2021, 20, 82-85.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Bronchial Angioembolization for Management of Hemoptysis Due to Pulmonary Tuberculosis.. Tanaffos, 2021, 20, 134-139.	0.5	0
38	Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab.. Tanaffos, 2021, 20, 188-191.	0.5	1
39	NRITLD Protocol for the Management of Outpatient Cases of COVID-19.. Tanaffos, 2021, 20, 192-196.	0.5	0
40	Prevalence and Mechanisms of Carbapenem Resistance in <i>Acinetobacter baumannii</i> : A Comprehensive Systematic Review of Cross-Sectional Studies from Iran. Microbial Drug Resistance, 2020, 26, 270-283.	0.9	13
41	Iran's Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical Trials. Frontiers in Public Health, 2020, 8, 551889.	1.3	40
42	Silent hypoxia: higher NO in red blood cells of COVID-19 patients. BMC Pulmonary Medicine, 2020, 20, 269.	0.8	27
43	Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. International Immunopharmacology, 2020, 88, 106869.	1.7	40
44	Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. International Immunopharmacology, 2020, 89, 107102.	1.7	27
45	MiRNAs in tuberculosis: Their decisive role in the fate of TB. European Journal of Pharmacology, 2020, 886, 173529.	1.7	13
46	Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfusion and Apheresis Science, 2020, 59, 102875.	0.5	158
47	Extracorporeal membrane oxygenation and COVID-19: The causes of failure. Journal of Cardiac Surgery, 2020, 35, 2838-2843.	0.3	7
48	Prevalence and reversibility of smell dysfunction measured psychophysically in a cohort of COVID-19 patients. International Forum of Allergy and Rhinology, 2020, 10, 1127-1135.	1.5	81
49	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet, The, 2020, 396, 402-411.	6.3	49
50	Noninvasive Versus Invasive Ventilation in COVID-19: One Size Does Not Fit All!. Anesthesia and Analgesia, 2020, 131, e114-e115.	1.1	16
51	The Immune Response and Immunopathology of COVID-19. Frontiers in Immunology, 2020, 11, 2037.	2.2	137
52	Prevalence and Mechanisms of Carbapenem Resistance in <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> : A Systematic Review and Meta-Analysis of Cross-Sectional Studies from Iran. Microbial Drug Resistance, 2020, 26, 1491-1502.	0.9	18
53	Tocilizumab administration in a refractory case of COVID-19. International Journal of Antimicrobial Agents, 2020, 56, 106043.	1.1	15
54	Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. International Immunopharmacology, 2020, 85, 106688.	1.7	67

#	ARTICLE	IF	CITATIONS
55	Reply to: Psychophysical olfactory testing in COVID-19: is smell function really impaired in nearly all patients?. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 953-954.	1.5	7
56	Mendelian Susceptibility to Mycobacterial Disease (MSMD): Clinical and Genetic Features of 32 Iranian Patients. <i>Journal of Clinical Immunology</i> , 2020, 40, 872-882.	2.0	22
57	Smell dysfunction: a biomarker for COVID-19. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 944-950.	1.5	616
58	Proteomic and genomic biomarkers for Non-Small Cell Lung Cancer: Peroxiredoxin, Haptoglobin, and Alpha-1 antitrypsin. <i>Cancer Medicine</i> , 2020, 9, 3974-3982.	1.3	10
59	A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol. <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 31-36.	0.3	30
60	Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces. <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 1-2.	0.3	11
61	COVID-19 and Substance Use Disorders as Brain Diseases: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper. <i>Basic and Clinical Neuroscience</i> , 2020, 11, 133-150.	0.3	74
62	Immunopathogenesis of Pneumonia in COVID-19. <i>Tanaffos</i> , 2020, 19, 79-82.	0.5	5
63	Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View. <i>Tanaffos</i> , 2020, 19, 112-121.	0.5	0
64	A Novel Coronavirus Disease (COVID-19): a Review of Host Cell Signaling Pathways. <i>Tanaffos</i> , 2020, 19, 108-111.	0.5	4
65	Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran. <i>Tanaffos</i> , 2020, 19, 122-128.	0.5	3
66	NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. <i>Tanaffos</i> , 2020, 19, 91-99.	0.5	10
67	Oxygenation Efforts for Iranian COVID-19 ARDS Patients: First 5-Day Crisis Experience Scenario. <i>Tanaffos</i> , 2020, 19, 173-175.	0.5	0
68	Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients. <i>Tanaffos</i> , 2020, 19, 291-299.	0.5	1
69	Clinical Features and Outcomes of ICU Patients with COVID-19 Infection in Tehran, Iran: a Single-Centered Retrospective Cohort Study. <i>Tanaffos</i> , 2020, 19, 300-311.	0.5	4
70	Blastocystis subtype 1 (allele 4); Predominant subtype among tuberculosis patients in Iran. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2019, 65, 201-206.	0.7	22
71	Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in Iranian population. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 594-602.	0.7	4
72	Common Infections and Target Organs Associated with Chronic Granulomatous Disease in Iran. <i>International Archives of Allergy and Immunology</i> , 2019, 179, 62-73.	0.9	24

#	ARTICLE	IF	CITATIONS
73	Serum Exosomal miRNAs Are Associated with Active Pulmonary Tuberculosis. <i>Disease Markers</i> , 2019, 2019, 1-9.	0.6	48
74	Frequency, associated factors and clinical symptoms of intestinal parasites among tuberculosis and non-tuberculosis groups in Iran: a comparative cross-sectional study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 234-241.	0.7	25
75	Three Markers in Cancerous and Healthy Cells of Patients with Non-Small-Cell Lung Carcinoma (NSCLC). <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2281-2285.	0.5	3
76	Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2019, 12, 138-142.	0.6	10
77	Trends in multidrug-resistant tuberculosis in Tehran, Iran: an analysis of published data. <i>GMS Hygiene and Infection Control</i> , 2019, 14, Doc11.	0.2	1
78	Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-performance Liquid Chromatography and UV Detection. <i>Iranian Journal of Pharmaceutical Research</i> , 2019, 18, 1735-1741.	0.3	3
79	Etiology of Respiratory Complications among Iranian HIV Infected Patients. <i>Tanaffos</i> , 2019, 18, 96-103.	0.5	0
80	Enterovirus-Human Rhinovirus as a Leading Cause of ARDS in a Liver Transplant Recipient. <i>Tanaffos</i> , 2019, 18, 169-172.	0.5	0
81	Toothpick Aspiration Induces Massive Hemoptysis: a Case Report. <i>Tanaffos</i> , 2019, 18, 369-372.	0.5	0
82	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 265-275.	5.2	80
83	Diagnosing active and latent tuberculosis among Iranian HIV-infected patients. <i>Clinical Respiratory Journal</i> , 2018, 12, 62-67.	0.6	2
84	Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity. <i>Human Immunology</i> , 2018, 79, 63-69.	1.2	54
85	Risk factors for mortality among tuberculosis patients co-infected with HIV. <i>Infectious Diseases</i> , 2018, 50, 399-402.	1.4	0
86	Cellular immune response in MDR-TB patients to different protein expression of MDR and susceptible <i>Mycobacterium tuberculosis</i> : Rv0147, a novel MDR-TB biomarker. <i>Immunologic Research</i> , 2018, 66, 59-66.	1.3	6
87	An adult autosomal recessive chronic granulomatous disease patient with pulmonary <i>Aspergillus terreus</i> infection. <i>BMC Infectious Diseases</i> , 2018, 18, 552.	1.3	5
88	Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center. <i>Interventional Medicine &amp; Applied Science</i> , 2018, 11, 1-7.	0.2	1
89	Human IFN- $\gamma$ immunity to mycobacteria is governed by both IL-12 and IL-23. <i>Science Immunology</i> , 2018, 3, .	5.6	152
90	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	6.3	452

#	ARTICLE	IF	CITATIONS
91	Revision and Implementation of "Clinical Guideline for Tuberculosis and HIV in Prisons", Great Tehran Prison, Iran. <i>Infectious Disorders - Drug Targets</i> , 2018, 18, 72-80.	0.4	11
92	Implementing tuberculosis close-contact investigation in a Tertiary Hospital in Iran. <i>International Journal of Preventive Medicine</i> , 2018, 9, 48.	0.2	4
93	Investigating PIKR and ATpA Genes Expressions in Ventilator-Associated Pneumonia Patients Admitted to the Intensive Care Unit of Masih Daneshvari Hospital in 2016. <i>Reports of Biochemistry and Molecular Biology</i> , 2018, 6, 118-124.	0.5	3
94	Risk Factors Associated with Survival of Pulmonary Tuberculosis. <i>Iranian Journal of Public Health</i> , 2018, 47, 980-987.	0.3	2
95	Immunocompromised patients with pulmonary tuberculosis; a susceptible group to intestinal parasites. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2018, 11, S134-S139.	0.6	16
96	Study Protocol on Antimicrobial Stewardship in a Tertiary Respiratory Referral Hospital. <i>Tanaffos</i> , 2018, 17, 183-187.	0.5	0
97	Caspofungin as Salvage Therapy for Pneumocystis Pneumonia in a Heart Transplant Recipient. <i>Tanaffos</i> , 2018, 17, 203-206.	0.5	2
98	miR-1224 Expression Is Increased in Human Macrophages after Infection with Bacillus Calmette-Guérin (BCG). <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2018, 17, 250-257.	0.3	6
99	Pattern recognitions receptors in immunodeficiency disorders. <i>European Journal of Pharmacology</i> , 2017, 808, 49-56.	1.7	23
100	Paecilomyces formosus Infection in an Adult Patient with Undiagnosed Chronic Granulomatous Disease. <i>Journal of Clinical Immunology</i> , 2017, 37, 342-346.	2.0	13
101	Bovis Bacillus Calmette-Guérin (BCG) infection induces exosomal miRNA release by human macrophages. <i>Journal of Translational Medicine</i> , 2017, 15, 105.	1.8	51
102	Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 11, 116-119.	0.9	1
103	Cost of Tuberculosis Treatment: Evidence from Iran's Health System. <i>Osong Public Health and Research Perspectives</i> , 2017, 8, 351-357.	0.7	7
104	Acute Epstein - Barr virus hepatitis without mononucleosis syndrome: a case report. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2017, 10, 147-149.	0.6	5
105	Cancers Related to Immunodeficiencies: Update and Perspectives. <i>Frontiers in Immunology</i> , 2016, 7, 365.	2.2	137
106	Susceptibility to pulmonary tuberculosis: host genetic deficiency in tumor necrosis factor alpha (TNF- $\alpha$ ) gene and tumor necrosis factor receptor 2 (TNFR2). <i>International Journal of Mycobacteriology</i> , 2016, 5, S136-S137.	0.3	7
107	T cell cytokine responses in peripheral blood mononuclear cells from patients with multidrug-resistant tuberculosis following stimulation with proteins purified from Mycobacterium tuberculosis MDR clinical isolates. <i>International Journal of Mycobacteriology</i> , 2016, 5, S132-S133.	0.3	2
108	ISG15 deficiency and increased viral resistance in humans but not mice. <i>Nature Communications</i> , 2016, 7, 11496.	5.8	156

#	ARTICLE	IF	CITATIONS
109	Using competing risks model and competing events in outcome of pulmonary tuberculosis patients. <i>International Journal of Mycobacteriology</i> , 2016, 5, S237.	0.3	1
110	Yield of mycobacteriological study in diagnosis of pleural tuberculosis among Human immune deficiency virus-infected patients. <i>International Journal of Mycobacteriology</i> , 2016, 5, S112-S113.	0.3	3
111	Usefulness of pulmonary artery diameter in diagnosing pulmonary hypertension in patients admitted to tuberculosis intensive care unit. <i>International Journal of Mycobacteriology</i> , 2016, 5, S56.	0.3	1
112	Investigation of urine lipoarabinomannan in human immunodeficiency virus patients with or without coinfection with Tuberculosis in Iran. <i>International Journal of Mycobacteriology</i> , 2016, 5, S186-S187.	0.3	3
113	Radiographic manifestations of Tuberculosis in HIV positive patients: Correlation with CD4+ T-cell count. <i>International Journal of Mycobacteriology</i> , 2016, 5, S244-S245.	0.3	7
114	Molecular drug susceptibility testing against the first-line (rifampin and isoniazid) and second-line (ciprofloxacin, amikacin and kanamycin) treatment in different subtypes of <i>Mycobacterium simiae</i> . <i>International Journal of Mycobacteriology</i> , 2016, 5, S215.	0.3	2
115	The analysis of exosomal micro-RNAs in peripheral blood mononuclear cell-derived macrophages after infection with bacillus Calmette-Guérin by RNA sequencing. <i>International Journal of Mycobacteriology</i> , 2016, 5, S184-S185.	0.3	9
116	A randomized controlled trial of smoking cessation methods in patients newly-diagnosed with pulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2016, 16, 369.	1.3	25
117	HIV and tuberculosis trends and survival of coinfection in a referral center in Tehran: A 12-year study. <i>International Journal of Mycobacteriology</i> , 2016, 5, S16-S17.	0.3	4
118	Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 4, 1-4.	0.9	17
119	Impact of HIV infection on tuberculous pleural effusion. <i>International Journal of STD and AIDS</i> , 2016, 27, 363-369.	0.5	14
120	Intention to Quit Smoking and Associated Factors in Smokers Newly Diagnosed with Pulmonary Tuberculosis. <i>Tanaffos</i> , 2016, 15, 17-24.	0.5	11
121	Estimation of Ten-Year Survival of Patients with Pulmonary Tuberculosis Based on the Competing Risks Model in Iran. <i>Tanaffos</i> , 2016, 15, 37-43.	0.5	1
122	Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients. <i>Tanaffos</i> , 2016, 15, 48-52.	0.5	4
123	Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. <i>Iranian Journal of Pharmaceutical Research</i> , 2016, 15, 247-52.	0.3	21
124	H1N1 Influenza Patient Saved by Extracorporeal Membrane Oxygenation: First Report from Iran. <i>The Journal of Tehran Heart Center</i> , 2016, 11, 153-156.	0.3	2
125	Tuberculosis in Solid Organ Transplantation. <i>Tanaffos</i> , 2016, 15, 124-127.	0.5	4
126	Reduced Phagocytic Capacity of Blood Monocyte/Macrophages in Tuberculosis Patients Is Further Reduced by Smoking. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2016, 15, 174-82.	0.3	17



#	ARTICLE	IF	CITATIONS
127	Screening for diabetes mellitus in tuberculosis patients in a referral center in Iran. <i>Infectious Diseases</i> , 2015, 47, 472-476.	1.4	6
128	Detection of latent and active tuberculosis among HIV-positive patients at the North of Tehran. <i>International Journal of Mycobacteriology</i> , 2015, 4, 64.	0.3	0
129	Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. <i>International Journal of Mycobacteriology</i> , 2015, 4, 128.	0.3	1
130	Outcome of drug-resistant tuberculosis treatment among HIV-positive patients at the tertiary center in Tehran. <i>International Journal of Mycobacteriology</i> , 2015, 4, 115.	0.3	0
131	Radiologic manifestations of pulmonary tuberculosis in patients of intensive care units. <i>International Journal of Mycobacteriology</i> , 2015, 4, 233-238.	0.3	11
132	Default of treatment in patients with tuberculosis during 10years after standardized drug treatment. <i>International Journal of Mycobacteriology</i> , 2015, 4, 164.	0.3	0
133	First report of occurrence of <i>Mycobacterium tuberculosis</i> and Non-tuberculous mycobacteria in a heterozygous carrier of chronic granulomatous patient. <i>International Journal of Mycobacteriology</i> , 2015, 4, 150.	0.3	1
134	Interaction of Pattern Recognition Receptors with <i>Mycobacterium Tuberculosis</i> . <i>Journal of Clinical Immunology</i> , 2015, 35, 1-10.	2.0	129
135	Disseminated Kaposi's sarcoma with the involvement of penis in the setting of Hiv infection. <i>Indian Journal of Dermatology</i> , 2015, 60, 104.	0.1	5
136	Mycobacterial infection and the impact of rifabutin treatment in organ transplant recipients: A single-center study. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2015, 26, 6.	0.4	11
137	Comparison of antibacterial activities of cadmium oxide nanoparticles against <i>Pseudomonas Aeruginosa</i> and <i>Staphylococcus Aureus</i> bacteria. <i>Advanced Biomedical Research</i> , 2015, 4, 105.	0.2	13
138	Effect of Ventilation on Occupational Exposure to Airborne Biological Contaminants in an Isolation Room. <i>Tanaffos</i> , 2015, 14, 141-8.	0.5	1
139	Health Care Associated Middle East Respiratory Syndrome (MERS): A Case from Iran. <i>Tanaffos</i> , 2015, 14, 262-7.	0.5	8
140	Pulmonary <i>Paecilomyces</i> in a Diabetic Patient. <i>Tanaffos</i> , 2015, 14, 268-71.	0.5	6
141	Flow cytometry applications in the study of immunological lung disorders. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2015, 14, 12-8.	0.3	2
142	Invasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013. <i>JRSM Open</i> , 2014, 5, 204253331351768.	0.2	8
143	Elevated CXCL-8 expression in bronchoalveolar lavage correlates with disease severity in patients with acute respiratory distress syndrome resulting from tuberculosis. <i>Journal of Inflammation</i> , 2014, 11, 21.	1.5	19
144	Changes in glycosylated haemoglobin and treatment outcomes in patients with tuberculosis in Iran: a cohort study. <i>Journal of Diabetes and Metabolic Disorders</i> , 2014, 13, 123.	0.8	33

#	ARTICLE	IF	CITATIONS
145	Secondary infection and clinical aspects after pandemic swine-origin influenza a (H1N1) admission in an Iranian critical care unite. <i>International Journal of Critical Illness and Injury Science</i> , 2014, 4, 309.	0.2	3
146	Isolation of <i>Mycobacterium branderi</i> , an unusual species from an acute myelogenous leukemia patient. <i>Avicenna Journal of Medicine</i> , 2014, 4, 17.	0.3	5
147	Effect of pulmonary hypertension on outcome of pulmonary tuberculosis. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 487-490.	0.3	9
148	High Prevalence of Rifampin-Monoresistant Tuberculosis: A Retrospective Analysis among Iranian Pulmonary Tuberculosis Patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 90, 99-105.	0.6	33
149	Vulnerability of Homeless People in Tehran, Iran, to HIV, Tuberculosis and Viral Hepatitis. <i>PLoS ONE</i> , 2014, 9, e98742.	1.1	26
150	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Review Article. <i>Archives of Pediatric Infectious Diseases</i> , 2014, 3, .	0.1	0
151	The Effect of GarcinÂ® in Preventing AntiTB-Induced Hepatitis in Newly Diagnosed Tuberculosis Patients. <i>Iranian Journal of Pharmaceutical Research</i> , 2014, 13, 169-76.	0.3	7
152	Immunopathology of sarcoidosis. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2014, 13, 300-6.	0.3	8
153	Re: Interferon-gamma release assay agreement with tuberculin skin test in pretransplant screening for latent tuberculosis in a high-prevalence country. <i>Iranian Journal of Kidney Diseases</i> , 2014, 8, 432-3.	0.1	0
154	Multidrug resistant tuberculosis versus non-tuberculous mycobacterial infections: a CT-scan challenge. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 137-142.	0.3	10
155	Multidrug-resistant tubercular appendicitis: Report of a case. <i>International Journal of Mycobacteriology</i> , 2013, 2, 227-229.	0.3	1
156	Diabetes mellitus and tuberculosis facts and controversies. <i>Journal of Diabetes and Metabolic Disorders</i> , 2013, 12, 58.	0.8	90
157	Nocardiosis: Risk Factors, Clinical Characteristics and Outcome. <i>Iranian Red Crescent Medical Journal</i> , 2013, 15, 436-9.	0.5	22
158	Cutaneous Alternariosis With Trichosporon Infection in a Heart Transplant Recipient: A Case Report. <i>Experimental and Clinical Transplantation</i> , 2013, 11, 464-466.	0.2	3
159	A 26 year-old woman with AIDS and pneumonia. <i>Tanaffos</i> , 2013, 12, 61-3.	0.5	0
160	A 60 year-old man with AIDS and pneumonia. <i>Tanaffos</i> , 2013, 12, 61-2.	0.5	0
161	Colonization of <i>Pneumocystis jirovecii</i> in Chronic Obstructive Pulmonary Disease (COPD) patients and the rate of <i>Pneumocystis pneumonia</i> in Iranian non-HIV(+) immunocompromised patients. <i>Iranian Journal of Microbiology</i> , 2013, 5, 411-7.	0.8	6
162	Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia. <i>Indian Journal of Critical Care Medicine</i> , 2012, 16, 141-147.	0.3	20

#	ARTICLE	IF	CITATIONS
163	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	3.9	430
164	Value of third sputum smear for detection of pulmonary tuberculosis in HIV infected patients. <i>Gastroenterology Insights</i> , 2012, 4, 35.	0.7	1
165	Disseminated <i>Mycobacterium kansasii</i> in an HIV-negative patient. <i>International Journal of Mycobacteriology</i> , 2012, 1, 51-52.	0.3	1
166	Treatment outcome and mortality: Their predictors among HIV/TB co-infected patients from Iran. <i>International Journal of Mycobacteriology</i> , 2012, 1, 82-86.	0.3	7
167	Diagnostic yield of post-bronchoscopy sputum smear in pulmonary tuberculosis. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 369-373.	1.5	16
168	Extensively Drug-Resistant Tuberculosis: A Review Article. <i>Archives of Clinical Infectious Diseases</i> , 2012, 7, 81-4.	0.1	10
169	Comparison of Serum and Bronchoalveolar Lavage Galactomannan in Diagnosing Invasive Aspergillosis in Solid-Organ Transplant Recipients. <i>Experimental and Clinical Transplantation</i> , 2012, 10, 278-281.	0.2	29
170	A 43 year-old woman with Fever eleven years after kidney transplantation. <i>Tanaffos</i> , 2012, 11, 73-5.	0.5	1
171	Isoniazid Blood Levels in Patients with Pulmonary Tuberculosis at a Tuberculosis Referral Center. <i>Chemotherapy</i> , 2011, 57, 7-11.	0.8	18
172	Revised Category II Regimen as an Alternative Strategy for Retreatment of Category I Regimen Failure and Irregular Treatment Cases. <i>American Journal of Therapeutics</i> , 2011, 18, 343-349.	0.5	17
173	Adverse Effects of Multidrug-Resistant Tuberculosis Treatment With a Standardized Regimen: A Report From Iran. <i>American Journal of Therapeutics</i> , 2011, 18, e29-e34.	0.5	51
174	Lethal Tuberculosis in a Previously Healthy Adult with IL-12 Receptor Deficiency. <i>Journal of Clinical Immunology</i> , 2011, 31, 537-539.	2.0	49
175	Tuberculosis-Associated Secondary Pneumothorax: A Retrospective Study of 53 Patients. <i>Respiratory Care</i> , 2011, 56, 298-302.	0.8	28
176	Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection. <i>Annals of Thoracic Medicine</i> , 2011, 6, 91.	0.7	25
177	Utility of gastric lavage for diagnosis of tuberculosis in patients who are unable to expectorate sputum. <i>Journal of Global Infectious Diseases</i> , 2011, 3, 339.	0.2	15
178	Prevalence of Oseltamivir-Resistant 2009 H1N1 Influenza Virus among Patients with Pandemic 2009 H1N1 Influenza infection in NRITLD, Tehran, Iran. <i>Tanaffos</i> , 2011, 10, 8-11.	0.5	6
179	Clinical and Demographic Characteristics of Confirmed Cases in H1N1 (2009) Influenza. <i>Tanaffos</i> , 2011, 10, 15-9.	0.5	2
180	Improving the Practice of Nutrition Therapy in the NRITLD Critically Ill Patients: An International Quality Improvement Project. <i>Tanaffos</i> , 2011, 10, 31-7.	0.5	8

#	ARTICLE	IF	CITATIONS
181	A 60-year-old woman with pulmonary nodules. <i>Tanaffos</i> , 2011, 10, 69-72.	0.5	1
182	Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1235-1238.	0.8	87
183	Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases. <i>American Journal of Therapeutics</i> , 2010, 17, 17-22.	0.5	43
184	A Young Woman with Diffuse Skin Lesions. <i>Clinical Infectious Diseases</i> , 2010, 51, 195-196.	2.9	0
185	Impact of Extensively Drug-Resistant Tuberculosis on Treatment Outcome of Multidrug-Resistant Tuberculosis Patients with Standardized Regimen: Report from Iran. <i>Microbial Drug Resistance</i> , 2010, 16, 81-86.	0.9	22
186	Active pulmonary tuberculosis manifesting with idiopathic thrombocytopenic purpura: a rare presentation. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 639-640.	0.3	8
187	Prevalence of HPV and HIV among female drug addicts attending a drop-in center in Tehran, Iran. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 108, 254-255.	1.0	5
188	Coexisting venous thromboembolism in patients with tuberculosis. <i>Thrombosis Research</i> , 2010, 125, 478-480.	0.8	17
189	Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population. <i>International Journal of Infectious Diseases</i> , 2010, 14, e84-e85.	1.5	30
190	Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. <i>International Journal of Infectious Diseases</i> , 2010, 14, e399-e402.	1.5	16
191	Performance of QuantiFERON-TB Gold test compared to tuberculin skin test in detecting latent tuberculosis infection in HIV- positive individuals in Iran. <i>Annals of Thoracic Medicine</i> , 2010, 5, 43.	0.7	22
192	Serum Copper (Cu) Alterations in Pulmonary Tuberculosis Patients Under Treatment with Ethambutol. <i>Biological Trace Element Research</i> , 2009, 128, 161-166.	1.9	8
193	Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli. <i>Chest</i> , 2009, 136, 420-425.	0.4	524
194	Differences in Cell Wall Thickness between Resistant and Nonresistant Strains of <i>Mycobacterium tuberculosis</i> : Using Transmission Electron Microscopy. <i>Chemotherapy</i> , 2009, 55, 303-307.	0.8	115
195	Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 10-13.	1.5	7
196	First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance. <i>International Journal of Infectious Diseases</i> , 2009, 13, e236-e240.	1.5	69
197	Nontuberculous Mycobacteria Among Patients Who are Suspected for Multidrug-Resistant Tuberculosis—Need for Earlier Identification of Nontuberculous Mycobacteria. <i>American Journal of the Medical Sciences</i> , 2009, 337, 182-184.	0.4	35
198	The Recent-Transmission of <i>Mycobacterium tuberculosis</i> Strains among Iranian and Afghan Relapse Cases: a DNA-fingerprinting using RFLP and spoligotyping. <i>BMC Infectious Diseases</i> , 2008, 8, 109.	1.3	43

#	ARTICLE	IF	CITATIONS
199	Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran. <i>Respirology</i> , 2008, 13, 108-111.	1.3	5
200	Acute Necrotizing Pneumonia in a Previously Healthy Young Adult. <i>Clinical Infectious Diseases</i> , 2008, 46, 266-267.	2.9	2
201	Differences in characteristics between Afghani and Iranian patients with pulmonary tuberculosis. <i>International Journal of Infectious Diseases</i> , 2007, 11, 180-182.	1.5	3
202	Do mitochondrial DNA haplogroups play a role in susceptibility to tuberculosis?. <i>Respirology</i> , 2007, 12, 823-827.	1.3	4
203	Chronic Granulomatous Disease with Unusual Clinical Manifestation, Outcome, and Pattern of Inheritance in an Iranian Family. <i>Journal of Clinical Immunology</i> , 2006, 26, 291-296.	2.0	12
204	Inherited disorders of the IL-12-IFN- $\gamma$ axis in patients with disseminated BCG infection. <i>European Journal of Pediatrics</i> , 2005, 164, 753-757.	1.3	59
205	Primary Immune Deficiencies Presenting in Adults: Seven Years of Experience from Iran. <i>Journal of Clinical Immunology</i> , 2005, 25, 385-391.	2.0	28
206	Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. <i>International Journal of Infectious Diseases</i> , 2005, 9, 317-322.	1.5	44
207	Impact of clinical pharmacist-led antibiotic stewardship program on clinical outcomes in a tertiary referral hospital. <i>Journal of Pharmacy Practice and Research</i> , 0, , .	0.5	0